Ami Eyal, M.D. - Partner
Dr. Eyal is a senior surgeon with vast experience in medicine and life science as well as investment management. Since 1999, Dr. Eyal has been leading investments in the field of life sciences. Dr. Eyal is well-connected with leading international and Israeli figures in the fields of biomedicine and biotechnology. A former pilot in the Israeli Air Force, Dr. Eyal also served as deputy to the Israeli Air Force Surgeon General.

Gal Ehrlich, Ph.D., LLB - Partner
Dr. Ehrlich holds a Ph.D. in molecular biology and is recognized as the leading Israeli patent attorney in the life sciences field. Gal is a skilled expert in the evaluation and understanding of innovative technologies and their scientific and commercial relevance to the needs of the medical field. Gal’s intellectual property practice includes a team of more than 30 scientists, most of whom hold advanced degrees in Life Sciences and in related fields, such as physics, electronics, engineering, computer science, and chemistry.  

Keren Shtiegman, Ph.D. - Clinical & Regulatory Affairs Consultant
Dr. Shtiegman is a scientific regulatory and clinical affairs consultant with experience in the regulation of medical devices in the U.S and Europe .  Keren has gained experience in preparing and supporting clinical and regulatory strategies, and submissions. Keren has a broad scientific background. She obtained her Ph.D. in Molecular and Cellular Biology from the Weizmann Institute of Science, were she published her scientific work.

Merav Yarmus, Ph.D. - Clinical & Regulatory Affairs Consultant
Dr. Yarmus is a clinical and regulatory affairs specialist with a broad scientific background. 
Merav has gained practice in clinical and regulatory affairs of medical devices, including regulatory strategies, clinical packages, monitoring, pre-clinical studies and regulatory submissions. Merav acquired her Ph.D. on Food Technology, Molecular Biology and Microbiology from the Hebrew University of Jerusalem.  Following, Merav performed post-doctoral research in the Weizmann Institute of Science for four years focusing on Molecular and Cell Biology.

 
From seed to market approval, BioMedical Strategy has the best experts and international alliances to facilitate and optimize the regulatory process.